IMOH...XXII is not a true biotech stock. Its a hybrid. It will have a basic "staples" business with or without FDA, which can flourish elsewhere (outside the U.S.) and quite handsomely.
The biotech aspect is the FDA designation as VLN...which is just a bonus.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.